UGA Biopharma GmbH is a German company specialising in the development of monoclonal cell lines for the production of advanced biologics and biosimilars.

Established in 2009 and headquartered in Hennigsdorf, near Berlin, UGA Biopharma offers a comprehensive range of services and products to support the biopharmaceutical industry. Their expertise encompasses cell line development, upstream and downstream processing, analytical method development, and the provision of ready-to-use cell lines. The company is committed to delivering high-quality, cost-effective solutions tailored to the specific needs of their clients.

Key Products and Services:

• Cell Line Development: Utilising proprietary technology platforms, UGA Biopharma develops highly productive cell lines to support the production of premium-quality biopharmaceuticals.
• Upstream Processing: The company offers process development and optimisation services for cell lines, ensuring optimal product quality and yield.
• Downstream Processing: UGA Biopharma provides purification services with continuous monitoring of critical quality attributes, ensuring effective purification of proteins through individually scalable processes.
• Analytical Method Development: The company develops tailored analytical methods to determine productivity and critical quality attributes, supporting the biopharmaceutical development process.
• Ready-to-Use Cell Lines: UGA Biopharma offers high-quality, ready-to-use cell lines for biosimilars from their portfolio of specially adapted CHO host cell lines.
• First CHOice® Medium & Feeds: The company provides proprietary medium and accurately matched feed solutions, designed to enhance cell culture productivity and product quality.

UGA Biopharma’s dedication to quality and innovation positions it as a trusted partner in the biopharmaceutical industry, committed to advancing the development and production of life-saving biologics and biosimilars.